|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
EP3563872A1
(en)
|
2012-04-05 |
2019-11-06 |
Massachusetts Institute Of Technology |
Immunostimulatory compositions and methods of use thereof
|
|
ES2776698T3
(es)
|
2012-12-20 |
2020-07-31 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
WO2014179759A1
(en)
|
2013-05-03 |
2014-11-06 |
Ohio State Innovation Foundation |
Cs1-specific chimeric antigen receptor engineered immune effector cells
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
ES2741308T3
(es)
*
|
2013-10-15 |
2020-02-10 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
|
|
ES2845924T3
(es)
|
2013-10-15 |
2021-07-28 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
|
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
KR102606190B1
(ko)
|
2015-02-20 |
2023-11-23 |
오하이오 스테이트 이노베이션 파운데이션 |
Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
|
|
WO2016149254A1
(en)
|
2015-03-17 |
2016-09-22 |
Chimera Bioengineering, Inc. |
Smart car devices, de car polypeptides, side cars and uses thereof
|
|
WO2016154621A1
(en)
*
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
WO2016164370A1
(en)
|
2015-04-06 |
2016-10-13 |
Ohio State Innovation Foundation |
Egfr-directed car therapy for glioblastoma
|
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
CN114634943A
(zh)
|
2015-05-18 |
2022-06-17 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
ES2881771T3
(es)
|
2015-08-07 |
2021-11-30 |
Alx Oncology Inc |
Constructos que tienen un dominio de SIRP-alfa o variante del mismo
|
|
EP3352784A4
(en)
|
2015-09-23 |
2019-06-26 |
Cytoimmune Therapeutics, LLC |
FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
SG11201803173VA
(en)
|
2015-10-23 |
2018-05-30 |
Harvard College |
Nucleobase editors and uses thereof
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
CA3002674A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
CN108472365A
(zh)
*
|
2015-10-30 |
2018-08-31 |
艾丽塔生物治疗剂公司 |
用于肿瘤转导的组合物和方法
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
FI3377103T4
(fi)
*
|
2015-11-19 |
2025-04-16 |
Revitope Limited |
Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
|
|
GB201521393D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521389D0
(en)
*
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
|
GB201602974D0
(en)
*
|
2016-02-19 |
2016-04-06 |
Clube Jasper R |
Engineered cells & methods (1)
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
EP3458077A4
(en)
|
2016-05-17 |
2020-04-01 |
Chimera Bioengineering Inc. |
METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
|
|
US10501775B2
(en)
*
|
2016-07-12 |
2019-12-10 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
WO2018045177A1
(en)
*
|
2016-09-01 |
2018-03-08 |
Chimera Bioengineering, Inc. |
Gold optimized car t-cells
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
JP2020501512A
(ja)
*
|
2016-09-23 |
2020-01-23 |
ユニバーシティ オブ サザン カリフォルニア |
キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
GB2564823B8
(en)
|
2016-10-07 |
2022-06-29 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
|
AU2017345479B2
(en)
*
|
2016-10-19 |
2024-03-21 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
EP3315511A1
(en)
|
2016-10-29 |
2018-05-02 |
Miltenyi Biotec GmbH |
Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
|
|
CN108018299B
(zh)
*
|
2016-11-01 |
2020-03-17 |
上海恒润达生生物科技有限公司 |
靶向bcma的嵌合抗原受体及其用途
|
|
EP4464334A3
(en)
*
|
2016-11-07 |
2025-01-08 |
VIDAC Pharma Ltd. |
Use of compounds for treating hk2-expressing cancers
|
|
WO2018083704A1
(en)
|
2016-11-07 |
2018-05-11 |
Vidac Pharma Ltd. |
Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
CN107058315B
(zh)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
CA3048211A1
(en)
|
2016-12-23 |
2018-06-28 |
Macrogenics, Inc. |
Adam9-binding molecules, and methods of use thereof
|
|
CA3061898A1
(en)
|
2016-12-28 |
2019-10-29 |
Green Cross Lab Cell Corporation |
Chimeric antigen receptor and natural killer cells expressing same
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
SG11201907209QA
(en)
|
2017-02-08 |
2019-09-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
|
WO2018151817A2
(en)
*
|
2017-02-17 |
2018-08-23 |
Unum Therapeutics Inc. |
Co-use of anti-bcma antibody and antibody-coupled t celll receptor (actr) in cancer therapy and b cell disorders
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
CA3055202A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Cd19 compositions and methods for immunotherapy
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
AU2018256436B2
(en)
|
2017-04-19 |
2024-12-05 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
KR20200055037A
(ko)
*
|
2017-09-19 |
2020-05-20 |
메사추세츠 인스티튜트 오브 테크놀로지 |
키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
AU2018352592C1
(en)
|
2017-10-16 |
2025-09-25 |
Beam Therapeutics, Inc. |
Uses of adenosine base editors
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
US11117936B2
(en)
|
2017-11-10 |
2021-09-14 |
University of Pittsburg—Of the Commonwealth System of Higher Education |
Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
US12116417B2
(en)
|
2017-11-14 |
2024-10-15 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
JP6981234B2
(ja)
*
|
2017-12-22 |
2021-12-15 |
住友電装株式会社 |
バッテリターミナルカバー
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
CN112292138A
(zh)
|
2018-01-22 |
2021-01-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
Car t细胞的使用方法
|
|
SG11202007426XA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
US11110125B2
(en)
|
2018-02-13 |
2021-09-07 |
Chimera Bioengineering, Inc. |
Coordinating gene expression using RNA destabilizing elements
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
KR20210006330A
(ko)
|
2018-03-01 |
2021-01-18 |
유니버시티 오브 캔사스 |
재조합 t 세포 수용체 유전자를 사용하여 세포-기반 치료제를 생성하는 기술
|
|
WO2019195596A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
WO2019195586A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
KR102251028B1
(ko)
*
|
2018-04-18 |
2021-05-12 |
앱클론(주) |
스위치 분자 및 스위처블 키메라 항원 수용체
|
|
EP3561053A1
(en)
*
|
2018-04-26 |
2019-10-30 |
Baylor College of Medicine |
Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
US12448426B2
(en)
|
2018-05-17 |
2025-10-21 |
St. Jude Children's Research Hospital, Inc. |
Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
KR20190141511A
(ko)
|
2018-06-14 |
2019-12-24 |
주식회사 녹십자랩셀 |
신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
|
|
CA3108710A1
(en)
*
|
2018-08-07 |
2020-02-13 |
Purdue Research Foundation |
Rejuvenation of car t cell
|
|
CN114805356A
(zh)
*
|
2018-08-09 |
2022-07-29 |
中国医学科学院北京协和医院 |
用于控制嵌合抗原受体t细胞激活/抑制的连接臂及其应用
|
|
EP3620464A1
(en)
|
2018-09-10 |
2020-03-11 |
Miltenyi Biotec GmbH |
Car cell having crosslinked disulfide bridge on antigen recognizing moiety
|
|
KR20210068478A
(ko)
|
2018-09-28 |
2021-06-09 |
메사추세츠 인스티튜트 오브 테크놀로지 |
콜라겐-국재화된 면역조정성 분자 및 그의 방법
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
JP2022520106A
(ja)
|
2019-02-15 |
2022-03-28 |
ユニバーシティ オブ サザン カリフォルニア |
Ｌｙｍ－１およびｌｙｍ－２抗体組成物ならびに改善されたｃａｒ構築物
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
GB2601617B
(en)
|
2019-03-19 |
2024-02-21 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences
|
|
WO2020191305A2
(en)
|
2019-03-20 |
2020-09-24 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
|
JP7511573B2
(ja)
*
|
2019-03-27 |
2024-07-05 |
ナショナル リサーチ カウンシル オブ カナダ |
抗ｅｇｆｒｖｉｉｉ抗体及びその抗原結合断片
|
|
EP3946382A1
(en)
|
2019-04-04 |
2022-02-09 |
UMC Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
JP7710997B2
(ja)
|
2019-05-31 |
2025-07-22 |
エーエルエックス オンコロジー インコーポレイテッド |
免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20210046117A1
(en)
|
2019-08-18 |
2021-02-18 |
Chimera Bioengineering, Inc. |
Combination Therapy with Gold Controlled Transgenes
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
AU2020345943A1
(en)
|
2019-09-10 |
2022-03-31 |
Obsidian Therapeutics, Inc. |
CA2-IL15 fusion proteins for tunable regulation
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
EP3878464A1
(en)
|
2020-03-09 |
2021-09-15 |
Miltenyi Biotec B.V. & Co. KG |
Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
|
|
EP3881866A1
(en)
|
2020-03-16 |
2021-09-22 |
GEMoaB GmbH |
A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal
|
|
CN115397517A
(zh)
|
2020-04-17 |
2022-11-25 |
希望之城 |
用于治疗flt3阳性恶性肿瘤的靶向flt3的嵌合抗原受体修饰细胞
|
|
KR102502287B1
(ko)
*
|
2020-04-17 |
2023-02-22 |
앱클론(주) |
항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
BR112022024027A2
(pt)
*
|
2020-05-27 |
2023-02-07 |
Antion Biosciences Sa |
Moléculas adaptadoras para redirecionar células t car para um antígeno de interesse
|
|
DE112021003098T5
(de)
|
2020-06-03 |
2023-04-06 |
Kyocera Corporation |
Schneideinsatz, schneidwerkzeug, und verfahren zur herstellung eines maschinell bearbeiteten produkts
|
|
WO2022111562A1
(zh)
*
|
2020-11-26 |
2022-06-02 |
上海医药集团生物治疗技术有限公司 |
一种经修饰的免疫细胞及其应用
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
IL308400A
(en)
|
2021-05-13 |
2024-01-01 |
Alx Oncology Inc |
Combined therapies for cancer treatment
|
|
EP4176895A1
(en)
|
2021-11-08 |
2023-05-10 |
AvenCell Europe GmbH |
Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
|
|
US20250332258A1
(en)
*
|
2021-12-07 |
2025-10-30 |
The Scripps Research Institute |
Switchable car-t therapies for treating human cancers
|
|
CA3257334A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
PRODUCTION OF VIRAL PARTICLES
|
|
EP4342907A1
(en)
*
|
2022-09-21 |
2024-03-27 |
AvenCell Europe GmbH |
Switchable chimeric antigen receptors and their use
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024097992A2
(en)
|
2022-11-04 |
2024-05-10 |
Umoja Biopharma, Inc. |
Particles displaying adhesion-molecule fusions
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
US20250018037A1
(en)
*
|
2023-05-19 |
2025-01-16 |
Seoul National University R&Db Foundation |
Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025231174A1
(en)
|
2024-04-30 |
2025-11-06 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2025245374A1
(en)
*
|
2024-05-23 |
2025-11-27 |
The Nemours Foundation |
Peptidic chimeric antigen receptor effector cell adapters and uses thereof
|
|
NL2037809B1
(en)
|
2024-05-29 |
2025-12-12 |
Cell Control Biotherapeutics Inc |
Loop reinforcement expression system for improved cell therapy products
|